C. R. BARD LAUNCHES PATIENT-ORIENTED WEB SITE TO EDUCATE CONSUMERS ON NEW TREATMENTS FOR CHRONIC HEARTBURN
MURRAY HILL, NJ, -- November 17, 2000 -- C.R. Bard, Inc. (NYSE-BCR) today announced the launch of a patient-oriented Web site, www.endocinch.com containing valuable information about its innovative, incisionless alternative treatment for gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn. Through the speed of the Internet, consumers will discover that viewing the method that is now available to control the symptoms of chronic heartburn is just a few clicks away.
Visitors to the site will be able to see Bard's EndoCinch(tm) suturing system, a procedure which can significantly reduce the use of medication, relieve symptoms and decrease regurgitation for the 15 million American adults who suffer from chronic heartburn each day. Physicians using the EndoCinch(tm) system create plications, or pleats, near the "valve" at the top of the stomach in an outpatient procedure that allows for faster recovery time than standard procedures, thus enabling some patients to achieve freedom from symptoms in a matter of days, not weeks.
"Site visitors will learn more about Bard's EndoCinch(tm) system, currently being used at major medical centers all over the country to treat the painful, burning sensations of GERD in a user-friendly way," said Bard Chairman and Chief Executive Officer, William H. Longfield.
Bard's patient-oriented Web site will deliver the latest news and information on the EndoCinch(tm) system, including patient testimonials, along with educational material about GERD, and helpful links to heartburn-focused advocate groups. The site even includes a "Find a Physician" link which offers patients the opportunity to identify a physician in their area who offers the EndoCinch(tm) system simply by entering in their state. Bard is launching this web site prior to National GERD Week, November 19-25, 2000, to allow GERD sufferers to get helpful information about their condition.
C.R. Bard, Inc. (www.crbard.com) headquartered in Murray Hill, New Jersey, is a leading multinational developer, manufacturer and marketer of healthcare products in the fields of vascular, urology, oncology and surgical specialty products.
Bard Interventional Products, a division of Bard, is located in Billerica, Massachusetts, and specializes in the field of gastroenterology. For more than ten years, Bard Interventional Products has been developing minimally invasive diagnostic and therapeutic products used in conjunction with procedures requiring flexible endoscopy.
About C. R. Bard, Inc.
C. R. Bard, Inc., headquartered in Murray Hill, New Jersey, is a leading multinational developer, manufacturer and marketer of healthcare products. Bard Endoscopic Technologies, headquartered in Billerica, MA, is a division of C. R. Bard, Inc. (NYSE-BCR), specializing in the field of gastroenterology. For more than ten years, Bard Endoscopic Technologies (formerly Bard Interventional Products) has been developing minimally invasive diagnostic and therapeutic products used in conjunction with procedures requiring flexible endoscopy. Visit the company website at www.crbard.com.
Find a Physician
